Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review

  • Authors:
    • Tian'an Jiang
    • Qiyu Zhao
    • Guo Tian
    • Xinhua Chen
    • Liming Wu
  • View Affiliations

  • Published online on: July 17, 2019     https://doi.org/10.3892/etm.2019.7780
  • Pages: 2243-2249
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metastatic retroperitoneal tumors constitute an end‑stage disease with poor prognosis that represents a heavy global health burden. The present study aimed to explore the efficacy of irreversible electroporation ablation (IRE) therapy in patients with end‑stage retroperitoneal tumors. Between April 2016 and September 2017, three patients with unresectable retroperitoneal malignant tumors were enrolled. Among these cases, ultrasound (US)‑guided IRE was palliatively performed for targeting 3 tumors (1 tumor per patient) located around the abdominal aorta. Post‑treatment contrast‑enhanced US (CEUS) and contrast‑enhanced computed tomography (CECT) scans were subsequently performed to evaluate the area adjacent to the ablation zone and determine the prognosis. During the follow‑up, the cases experienced a reduction of pain (mean score of 5.8 decreased to 2.2, based on the visual analogue scale), and had an overall survival rate ranging from 2 to 11 months. Case 1 remained alive at the time of submission of this study, but case 2 died within 2 months and case 3 within 11 months due to liver metastases of the primary tumor. At the 3‑week follow‑up, the CEUS image for case 1 exhibited a contrast defect with a sufficient ablation margin, in accordance with the CECT at 1.5 months following IRE, exhibiting complete tumor necrosis without contrast enhancement. Overall, these results suggest that US‑guided percutaneous IRE may be effective in the treatment of end‑stage retroperitoneal tumors. However, further studies are required to substantiate the conclusions of the present study. The present clinical trial was registered at clinicaltrials.gov (ID: NCT02822066) on June 20th, 2016.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jiang, T., Zhao, Q., Tian, G., Chen, X., & Wu, L. (2019). Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review. Experimental and Therapeutic Medicine, 18, 2243-2249. https://doi.org/10.3892/etm.2019.7780
MLA
Jiang, T., Zhao, Q., Tian, G., Chen, X., Wu, L."Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review". Experimental and Therapeutic Medicine 18.3 (2019): 2243-2249.
Chicago
Jiang, T., Zhao, Q., Tian, G., Chen, X., Wu, L."Irreversible electroporation ablation of end‑stage metastatic retroperitoneal lesions: Report on three cases and literature review". Experimental and Therapeutic Medicine 18, no. 3 (2019): 2243-2249. https://doi.org/10.3892/etm.2019.7780